Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Pentech Phar Inc v. Par Phar Inc (N.D. Ill. 2004)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Pentech Phar Inc v. Par Phar Inc (N.D. Ill. 2004)

Docket   Start Trial Date Filed 2004-05-03
Court District Court, N.D. Illinois Date Terminated 2009-02-09
Cause 28:1332 Diversity-Breach of Contract Assigned To Honorable Morton Denlow
Jury Demand Both Referred To
Patents 4,721,723; 6,080,759
Attorneys Eric Neal Macey; Evan R. Chesler; James Jerome Hartzell; John F. Shonkwiler; Kedric L. Payne; Matthew S. Miller; Michael P Burke; Michael Thomas Layden; Patrick A. Fleming; Rajeev K Adlakha; Richard A. Edlin; Richard J. Prendergast; Roger G. Brooks; Stephen V. Potenza; Vincent Michael Roche
Firms Cravath, Swaine & Moore LLP; Greenberg Traurig LLP; Hartzell and Whiteman; Law Offices of Matthew S. Miller; Novack & MacEy; Novack and MacEy, LLP; Richard J. Prendergast, Ltd.
Link to Docket External link to docket
Small Molecule Drugs cited in Pentech Phar Inc v. Par Phar Inc
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Pentech Phar Inc v. Par Phar Inc (N.D. Ill. 2004)

Date Filed Document No. Description Snippet Link To Document
2009-02-09 295 memorandum opinion and order alleged that it was the owner of a patent (Patent Nos. 4,721,723 and 6,080,759), and, in each case, … infringe GSK’s paroxetine patents. In 1997, Pentech was awarded a patent for a paroxetine composition…submitted applications for two additional patents on paroxetine, and patents on these applications were ultimately…one of GSK’s patents that was due to expire in 2006, and further admitted that the patents were valid …treatment of depression, among other things. GSK owns patent rights concerning Paxil. Paxil was approved by External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.